Evidence map›Paper›PMID 29844839›Full record

ArticleOncology letters2018

Evaluation of latent membrane protein 1 and microRNA-155 for the prognostic prediction of diffuse large B cell lymphoma.

Xue Wu, Fei Wang, Yuan Li, Xiyong Wang, Ping Liu, Haijun Zhang, Zheng Ge, Xiaoping Zhang, Chong Gao, Baoan Chen

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Xue WuDepartment of Hematology (Key Department of Jiangsu Medicine), Medical School, The Affiliated Zhongda Hospital, Southeast University, Nanjing, Jiangsu 210009, P.R. China.
Fei WangDepartment of Hematology (Key Department of Jiangsu Medicine), Medical School, The Affiliated Zhongda Hospital, Southeast University, Nanjing, Jiangsu 210009, P.R. China.
Yuan LiDepartment of Oncology, Medical School, The Affiliated Zhongda Hospital, Southeast University, Nanjing, Jiangsu 210009, P.R. China.
Xiyong WangDepartment of Oncology, Medical School, The Affiliated Zhongda Hospital, Southeast University, Nanjing, Jiangsu 210009, P.R. China.
Ping LiuDepartment of Hematology (Key Department of Jiangsu Medicine), Medical School, The Affiliated Zhongda Hospital, Southeast University, Nanjing, Jiangsu 210009, P.R. China.
Haijun ZhangDepartment of Oncology, Medical School, The Affiliated Zhongda Hospital, Southeast University, Nanjing, Jiangsu 210009, P.R. China.
Zheng GeDepartment of Hematology (Key Department of Jiangsu Medicine), Medical School, The Affiliated Zhongda Hospital, Southeast University, Nanjing, Jiangsu 210009, P.R. China.
Xiaoping ZhangDepartment of Hematology (Key Department of Jiangsu Medicine), Medical School, The Affiliated Zhongda Hospital, Southeast University, Nanjing, Jiangsu 210009, P.R. China.
Chong GaoDepartment of Hematology (Key Department of Jiangsu Medicine), Medical School, The Affiliated Zhongda Hospital, Southeast University, Nanjing, Jiangsu 210009, P.R. China.
Baoan ChenDepartment of Hematology (Key Department of Jiangsu Medicine), Medical School, The Affiliated Zhongda Hospital, Southeast University, Nanjing, Jiangsu 210009, P.R. China.
Zhongda Hospital Southeast University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diffuse large B cell lymphoma (DLBCL) has previously been demonstrated to contribute to the mortality of lymphoma with various aggressive features. The prognostic role of the biomarkers latent membrane protein (LMP) 1 and microRNA-(miR)-155 in DLBCL remain controversial. The present study primarily aimed to assess the effect of LMP1 and miR-155 on the survival of DLBCL patients, and additionally evaluate the clinical features to observe their influence on outcomes, compared with previous studies. Formalin-fixed and paraffin-embedded samples were collected from our center between May 2010 and December 2011. Microarray analysis, immunohistochemical analysis and reverse transcription-quantitative polymerase chain reaction were used to evaluate the expression of LMP1 and miR-155. The association between biomarkers or clinical features and patient outcomes was assessed using the log-rank statistical test, Cox proportional hazard model and Kaplan-Meier method. SPSS software was used to statistically analyze the data. A total of 82 patients were included in the present study. The results demonstrated that high expression of LMP1 and miR-155 may be associated with a poor progression-free survival rate, while a high International Prognostic Index score and high expression of LMP1 may be associated with a poor overall survival rate. These results indicated that LMP1 and miR-155 may be novel and reliable biomarkers for the prognostic prediction of lymphoma, and will potentially be analyzed in the future to evaluate patient prognosis.

Indexed as

latent membrane protein 1lymphomamicroRNA-155predictorprognosis

Identifiers

PMID29844839
PMCPMC5958882
OpenAlexW2800106346

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.